Why the study?
Do novel pyridazinyl oxime ethers (BTA39 and BTA188) inhibit picornaviruses in vitro?
Do novel pyridazinyl oxime ethers (BTA39 and BTA188) inhibit picornaviruses in vitro?
Novel orally bioavailable pyridazinyl oxime ethers (BTA39 and BTA188) demonstrate potent in vitro antiviral activity against human rhinovirus and enteroviruses with low cytotoxicity.
No takes yet. Share an insight, caveat, or question.
BTA39 and BTA188 show potent in vitro anti-HRV activity with low cytotoxicity; leaves open clinical translation pending in vivo studies.
Barnard et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: